Anthropometric, clinical, and laboratory data in NAFLD patients, type 2 diabetic patients, and control subjects
| NAFLD patients | Type 2 diabetic patients | Control subjects | |
|---|---|---|---|
| n | 30 | 10 | 10 |
| Sex (M/F) | 24/6 | 8/2 | 8/2 |
| Age (years) | 41 ± 11 (24–64)* | 56 ± 8 (45–67) | 48 ± 14 (26–60) |
| Weight (kg) | 81 ± 10 (65–96) | 84 ± 10 (66–105) | 73 ± 11 (57–94) |
| BMI (kg/m2) | 27 ± 2 (23–29)† | 29 ± 4 (24–37)† | 24 ± 2 (21–28) |
| Waist circumference (cm) | 100 ± 8 (87–115)† | 98 ± 8 (77–109) | 85 ± 12 (73–100) |
| Hip circumference (cm) | 106 ± 6 (94–117) | 109 ± 10 (100–135) | 101 ± 6 (90–109) |
| Waist-to-hip ratio | 0.94 ± 0.06 (0.80-1.08)† | 0.92 ± 0.09 (0.71–1.04) | 0.84 ± 0.10 (0.71–0.95) |
| Fasting glucose (mmol/l) | 5.2 ± 0.5 (4.4–6.0)* | 6.3 ± 0.4 (5.7–7.1)† | 5.0 ± 0.4 (4.4–5.7) |
| 120-min OGTT glucose (mmol/l) | 5.7 ± 0.9 (4.1–7.2) | Not determined | 5.9 ± 0.8 (4.7–7.2) |
| Total cholesterol (mmol/l) | 5.5 ± 1.1 (3.9–9.1) | 5.0 ± 0.8 (4.0–6.5) | 4.9 ± 0.9 (3.4–5.9) |
| HDL cholesterol (mmol/l) | 1.1 ± 0.3 (0.7–2.1)† | 1.0 ± 0.2 (0.7–1.4)† | 1.5 ± 0.3 (1.0–2.1) |
| Triglycerides (mmol/l) | 2.3 ± 1.0 (0.9–4.9)† | 2.3 ± 1.2 (0.7–4.3)† | 1.1 ± 0.4 (0.6–1.6) |
| Uric acid (μmol/l) | 349 ± 64 (208–476)† | 358 ± 73 (227–479)† | 235 ± 59 (156–329) |
| Fasting insulin (pmol/l) | 124 ± 58 (43–265)† | 143 ± 59 (86–258)† | 44 ± 20 (14–79) |
| Fasting C-peptide (pmol/ml) | 1,080 ± 236 (719–1,548)† | 900 ± 298 (525–1,548)† | 677 ± 200 (498–1,161) |
| AST (units/l) | 42 ± 16 (25–98)†* | 19 ± 7 (12–29) | 16 ± 5 (10–22) |
| ALT (units/l) | 90 ± 40 (44–203)†* | 29 ± 10 (15–44) | 22 ± 7 (12–33) |
Data are means ± SD (range). Normal AST and ALT values <40 units/l.
* P < 0.005 vs. patients with type 2 diabetes;
† P < 0.005 vs. control subjects.